Expert Review of Pharmacoeconomics & Outcomes Research最新文献

Cost-effectiveness analysis of 20-valent anti-pneumococcal vaccination in the Spanish pediatric population. 西班牙儿科人群中20价抗肺炎球菌疫苗的成本-效果分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-24 DOI: 10.1080/14737167.2025.2521445

Franciso Álvarez García, Federico Martinón-Torres, Valentí Pineda, Alejandra López-Ibáñez de Aldecoa, Paulina Gálvez, An Ta, Johnna Perdrizet

{"title":"Cost-effectiveness analysis of 20-valent anti-pneumococcal vaccination in the Spanish pediatric population.","authors":"Franciso Álvarez García, Federico Martinón-Torres, Valentí Pineda, Alejandra López-Ibáñez de Aldecoa, Paulina Gálvez, An Ta, Johnna Perdrizet","doi":"10.1080/14737167.2025.2521445","DOIUrl":"10.1080/14737167.2025.2521445","url":null,"abstract":"Objectives: We evaluated the cost-effectiveness of implementing different pneumococcal conjugate vaccines (PCV) - 20-valent (PCV20; 3 + 1), 13-valent (PCV13; 2 + 1), and 15-valent (PCV15; 2 + 1) - into the Spanish pediatric national immunization program (NIP) for pneumococcal disease prevention.Methods: A Markov model adopting a Spanish National Healthcare System perspective and annual cycles estimated the health and cost impact of PCV20, PCV13, and PCV15 over 10 years among children. Epidemiological, cost, and utility inputs were derived from published literature and official databases; vaccine efficacy inputs were based on PCV13 clinical effectiveness and 7-valent PCV efficacy and impact studies. Sensitivity analyses evaluated model robustness.Results: PCV20 implementation was predicted to reduce the pneumococcal disease burden, preventing > 1,000,000 pneumococcal disease cases and > 150 deaths, versus both comparators. The adoption of PCV20 was estimated to result in cost-savings of approximately €1 billion versus PCV13 and PCV15. PCV20 demonstrated dominance over both alternatives, with 100% of 1,000 probabilistic sensitivity analysis iterations indicating PCV20 dominance.Conclusion: Incorporating PCV20 3 + 1 into the Spanish pediatric NIP was predicted to be more effective at a lower cost than PCV13 2 + 1 and PCV15 2 + 1 due to its broader serotype coverage and enhanced protection against pneumococcal disease.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-13"},"PeriodicalIF":1.8,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers. 了解生存率的上限，以指导和批判性地评估低风险癌症的经济评估。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-24 DOI: 10.1080/14737167.2025.2522326

Xuanqian Xie, Ishita Joshi, Myra Wang, Chunmei Li

{"title":"Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers.","authors":"Xuanqian Xie, Ishita Joshi, Myra Wang, Chunmei Li","doi":"10.1080/14737167.2025.2522326","DOIUrl":"10.1080/14737167.2025.2522326","url":null,"abstract":"Background: In most developed countries, overall survival rates for low-risk cancers (e.g. localized prostate and thyroid cancer) are comparable to those of the general population. The general population's survival rate may serve as an upper bound for survival in people with these cancers.Methods: By applying this concept, we demonstrated limitations of using Markov models for low-risk cancers and proposed an alternative modeling approach.Results: Markov disease progression models typically depict a gradual progression from early to advanced cancer stages and an increasing risk of cancer-specific mortality over time. However, data showed that the risk of death from cancer was often the greatest within the first few years following diagnosis. We therefore proposed an alternative modeling approach. This method involves calculating the average quality-adjusted life-years (QALYs) from the integrals of the survival curve, multiplied by the corresponding health utility curve. Alternatively, QALYs may be estimated by averaging survival and utility within each time interval and summing these estimates across intervals. We also applied these concepts to the critical appraisal of published economic evaluations.Conclusions: Understanding the upper bound of survival for low-risk cancers enables health economists to more accurately conduct cost-effectiveness analyses and assess the credibility of published economic evaluations. [Figure: see text].","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12C. 阿达格拉西联合或不联合西妥昔单抗治疗KRAS G12C突变的结直肠癌患者的成本-效果分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-23 DOI: 10.1080/14737167.2025.2521439

Ruihong Yao, Yao Yao, Xue Teng, Yao Jin, Shangwei Guan, Mei Dong, Tong Liu

{"title":"Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12C.","authors":"Ruihong Yao, Yao Yao, Xue Teng, Yao Jin, Shangwei Guan, Mei Dong, Tong Liu","doi":"10.1080/14737167.2025.2521439","DOIUrl":"10.1080/14737167.2025.2521439","url":null,"abstract":"Objectives: This study evaluates the cost-effectiveness of adagrasib plus cetuximab in contrast to adagrasib monotherapy in treating colorectal cancer (CRC) patients with mutated KRASG12C from the perspective of healthcare payers in the USA.Methods: An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of adagrasib plus cetuximab versus adagrasib monotherapy. The Kaplan-Meier curves for overall survival (OS) and progression-free survival (PFS) from a clinical trial were digitally extracted, and the Log-Logistic model was employed at the end of the trial to extrapolate the long-term survivals.Results: The estimated cost for adagrasib plus cetuximab treatment was higher than that of adagrasib monotherapy (290,645.434 USD vs 188,837.346 USD). The estimated utility was decreased compared to that of adagrasib monotherapy treatment (1.094 QALYs vs 1.359 QALYs). The ICER was calculated at -384,674.32 USD/QALY, suggesting the adagrasib plus cetuximab therapy did not demonstrate an economic advantage over adagrasib monotherapy for CRC patients with mutated KRASG12C.Conclusion: Adagrasib plus cetuximab was not cost-effective compared to adagrasib monotherapy as a late-line treatment for advanced or metastatic CRC patients with mutated KRASG12C in the USA.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methodological approaches in the economic evaluation of prognostic and predictive companion diagnostics: a systematic scoping review. 在预测和预测伴随诊断的经济评价的方法学方法：系统范围审查。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-22 DOI: 10.1080/14737167.2025.2519744

Tuukka Hakkarainen, Haavisto Ira, Leskelä Riikka-Leena

{"title":"Methodological approaches in the economic evaluation of prognostic and predictive companion diagnostics: a systematic scoping review.","authors":"Tuukka Hakkarainen, Haavisto Ira, Leskelä Riikka-Leena","doi":"10.1080/14737167.2025.2519744","DOIUrl":"10.1080/14737167.2025.2519744","url":null,"abstract":"Introduction: This systematic scoping review aimed to identify and analyze current methodological approaches used in model-based economic evaluations (EEs) of prognostic and predictive companion diagnostics (pCDx), highlighting methodological gaps and challenges.Methods: Systematic searches were conducted in PubMed and Scopus (January 2009-March 2023). Included studies were model-based EEs, methodological papers, or reviews specifically addressing prognostic or predictive CDx. Data extraction followed the modified CHEERS checklist. Results were synthesized narratively across six methodological domains. No formal risk of bias assessment was done per scoping review conventions.Results: Eighty-eight studies were included, of which 60 were model-based EEs. Most studies utilized Markov cohort models (37%) or decision tree-Markov hybrids (30%). Quality-adjusted life-years (QALYs) were the main outcome (88%). Only 15% of studies derived clinical utility from randomized controlled trials, and fewer than half explicitly modeled diagnostic accuracy. Methodological limitations included inconsistent modeling of real-world test-treatment pathways, insufficient consideration of pretest probabilities, diagnostic thresholds, and inadequate uncertainty analyses.Conclusions: This review identified variability and methodological gaps in economic evaluations of pCDx. Standardizing evaluation methods, integrating real-world evidence, and systematically considering the diagnostic accuracy and uncertainty could improve the robustness of pCDx evaluations. Limitations of this study included overrepresentation of breast cancer studies.Registration: OSF Registries (22 February 2023) DOI 10.17605/OSF.IO/GVFMQ.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-13"},"PeriodicalIF":1.8,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair. 腹疝修补手术后分层增强恢复路径的发展和实施。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-18 DOI: 10.1080/14737167.2025.2520409

James Espeleta, Sunitha Singh, Ethan Augustine, Artem Shmelev, Zhaosheng Jin, Daryn Moller

{"title":"Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair.","authors":"James Espeleta, Sunitha Singh, Ethan Augustine, Artem Shmelev, Zhaosheng Jin, Daryn Moller","doi":"10.1080/14737167.2025.2520409","DOIUrl":"10.1080/14737167.2025.2520409","url":null,"abstract":"Introduction: Enhanced recovery after surgery (ERAS) pathways are widely adopted in both major and minimally invasive surgeries. However, ERAS pathway implementation in ventral hernia repair (VHR) surgery remains an area of ongoing research given the variability in hernia complexity and surgical approach. To address this, our institution proposed and developed a stratified ERAS pathway to deliver effective, tailored perioperative care.Areas covered: This narrative describes the development of the ERAS pathway stratified to address the varied perioperative needs of VHR procedures, outline the evidence-based interventions comprising the bundle, describe the implementation process, and discuss the potential economic impact of implementing this pathway. We conducted a systematic literature search, last updated on 15 February 2024.Expert commentary: By leveraging the common elements of ventral hernia repair ERAS pathways, while addressing the perioperative needs of patients undergoing more complex procedures, a stratified pathway approach provides a practical and adaptable framework that balances intervention specificity with ease of implementation. While the introduction of conditional element modifications increases pathway complexity, it also facilitates patient-centered delivery of care. Operational expertise in organizing such pathways, as well as the implementation science behind it, is an opportunity to advance the frontiers of ERAS program developments.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-12"},"PeriodicalIF":1.8,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA. sotorasib联合帕尼单抗治疗美国KRAS G12C突变的难治性结直肠癌的成本-效果分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-17 DOI: 10.1080/14737167.2025.2521444

Tong Liu, Yao Yao, Xue Teng, Zhiqiang Tong, Mei Dong, Ruihong Yao

{"title":"Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA.","authors":"Tong Liu, Yao Yao, Xue Teng, Zhiqiang Tong, Mei Dong, Ruihong Yao","doi":"10.1080/14737167.2025.2521444","DOIUrl":"10.1080/14737167.2025.2521444","url":null,"abstract":"Background: This study evaluates the cost-effectiveness of sotorasib plus panitumumab in contrast to standard care in the treatment of refractory colorectal cancer (CRC) with mutated KRASG12Cfrom the perspective of healthcare payers in the U.S.A.Research design and methods: An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of sotorasib plus panitumumab versus standard care. TheKaplan-Meier curves for overall survival (OS) and progression-free survival(PFS) from a clinical trial were digitally extracted, and the Log-Logistic model was employed at the end of the trial to extrapolate the long-term survivals.Results: The estimated cost for sotorasib plus panitumumab treatment was higher than that of standard care treatment (77,087.936 USD vs 8905.065 USD). In addition, the estimated utility was relatively augmented than that of standard care treatment (0.876 QALYs vs 0.857 QALYs). The ICER was calculated at 3,551,555554USD/ QALY, suggesting the sotorasib plus panitumumab therapy did not demonstrate an economic advantage over standard care therapy for refractory CRC patients with mutated KRASG12C at the threshold of 150,000 USD/ QALY.Conclusions: Sotorasib plus panitumumab did not demonstrate an economic advantage compared to standard care in the treatment of refractory CRC with mutated KRASG12C in the U.S.A.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review. 低收入和中等收入国家对哮喘和慢性阻塞性肺病治疗的依从性：一项叙述性回顾

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-17 DOI: 10.1080/14737167.2025.2520898

Vaibhav Gaur, Alessandra Sorano, Himanshu Sankrityayan, Jaideep Gogtay, Federico Lavorini

{"title":"Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review.","authors":"Vaibhav Gaur, Alessandra Sorano, Himanshu Sankrityayan, Jaideep Gogtay, Federico Lavorini","doi":"10.1080/14737167.2025.2520898","DOIUrl":"10.1080/14737167.2025.2520898","url":null,"abstract":"Introduction: In low-income and middle-income countries (LIMCs), defined based on the World Bank classification, non-adherence to respiratory therapies contributes to increasing mortality and morbidity due to chronic respiratory diseases. To address this issue, it is essential to identify and tackle underlying factors such as cultural beliefs, socioeconomic disparities, and limited access to healthcare resources and infrastructures. The absence of strategies that integrate community involvement, healthcare professional's training, economic policies, and educational programs exacerbates the disproportionate burden of chronic respiratory diseases in LIMCs.Areas covered: This review is based on a structured literature search across PubMed, Scopus, and Google Scholar (2000-2023) using terms relevant to asthma, COPD, adherence, and LMICs. The review examines key factors that hinder patients' adherence to Asthma and COPD medications in LIMCs, providing some insights into the issue and proposing concrete solutions.Expert opinion: Addressing non-adherence requires a multifaceted approach involving community engagement, educational initiatives, and improved healthcare infrastructure. Future research should focus on tailored interventions to enhance adherence and ultimately improve health outcomes for patients with chronic respiratory diseases in LMICs.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":1.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation. 奥西替尼和达科替尼一线治疗晚期非小细胞肺癌EGFR突变的成本-效用分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-17 DOI: 10.1080/14737167.2025.2518135

Lili Su, Xiangyu Zhang, Mengrong Li, Ying Li, Dong Wang

{"title":"Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation.","authors":"Lili Su, Xiangyu Zhang, Mengrong Li, Ying Li, Dong Wang","doi":"10.1080/14737167.2025.2518135","DOIUrl":"10.1080/14737167.2025.2518135","url":null,"abstract":"Objective: To evaluate the cost-effectiveness of osimertinib compared to dacomitinib for advanced non-small cell lung cancer with EGFR mutation from the perspective of China's health system.Methods: Based on the FLAURA clinical trial and network meta-analysis, a partitioned survival model was constructed with a model simulation timeframe of 10 years and a 3-week cycle. Cost and quality-adjusted life years (QALYs) were used as model output indicators, and the incremental cost-effectiveness ratio was calculated to determine the economic feasibility of osimertinib compared to dacomitinib through cost-utility analysis. Sensitivity analysis was applied to test the robustness of the model.Results: The basic analysis results indicate that the osimertinib group incurred an additional cost of 138,487 Chinese Yuan (CNY) compared to the dacomitinib group, but gained an additional 0.32 QALYs. The incremental cost-effectiveness ratio is 436,203 CNY, which is higher than three times China's per capita GDP.Conclusion: Under the threshold of three times China's per capita GDP, osimertinib appears not to be cost-effective compared to dacomitinib.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and shiga prefecture. 20价肺炎球菌结合疫苗对日本和滋贺县66-84岁成人的健康和经济影响

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-13 DOI: 10.1080/14737167.2025.2519755

Tomoyuki Suzuki, Yoko Hirano, Kazumasa Kamei, Kayoko Miyata, Masahiro Kusama, Piotr Karwala, Camille Moyon, Catriona Crossan, Shuhei Ito, Jeffrey Vietri, Fumihiko Kakuno

{"title":"Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and shiga prefecture.","authors":"Tomoyuki Suzuki, Yoko Hirano, Kazumasa Kamei, Kayoko Miyata, Masahiro Kusama, Piotr Karwala, Camille Moyon, Catriona Crossan, Shuhei Ito, Jeffrey Vietri, Fumihiko Kakuno","doi":"10.1080/14737167.2025.2519755","DOIUrl":"https://doi.org/10.1080/14737167.2025.2519755","url":null,"abstract":"Background: The Japanese National Immunization Program against pneumococcal disease (PD) includes 23-valent pneumococcal polysaccharide vaccine (PPSV23) but does not provide vaccination for adults aged ≥66 years. We evaluated the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged 66-84 years with no history of PPSV23 vaccination in Japan and assessed the potential economic and health impact of introducing PCV20 on the local government (specifically, Shiga prefecture).Research design and methods: Using a Markov model, we assessed lifetime costs, quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by PD.Results: In national-level analysis, PCV20 was cost-effective compared with no vaccination under incremental cost-effectiveness ratio threshold of Japanese yen (JPY) 5,000,000/QALY, i.e. JPY1,677,401/QALY and JPY1,351,811/QALY from payer and societal perspectives, respectively. PCV20 was dominant (less costly and more effective) compared with PPSV23. In local-level analysis, the introduction of PCV20 required initial costs but resulted in greater cost savings related to medical expenses (-JPY424 and -JPY430 per person) and nursing care (-JPY560 and -JPY575 per person) compared to PPSV23 and no vaccination, respectively.Conclusions: PCV20 is cost-effective compared with PPSV23 and no vaccination in adults aged 66-84 years, which could reduce the future healthcare burden in Japan.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determinants of cancer drug prices in Germany and France: a multiple regression analysis. 德国和法国抗癌药物价格的决定因素：多元回归分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-12 DOI: 10.1080/14737167.2025.2518140

Nethra Subramanian, Aadhav Subramanian

{"title":"Determinants of cancer drug prices in Germany and France: a multiple regression analysis.","authors":"Nethra Subramanian, Aadhav Subramanian","doi":"10.1080/14737167.2025.2518140","DOIUrl":"10.1080/14737167.2025.2518140","url":null,"abstract":"Background: Higher prices for drugs targeting rarer cancers may be justified, but the extent remains uncertain. This research analyses the determinants of cancer drug prices in Germany and France.Research design and methods: Cancer drugs approved in EU between 2011 and 2022 with available benefit assessments and prices were analyzed. Monthly treatment cost was the dependent variable; approval year, orphan status, benefit rating, number of comparators, and target population size were independent variables. Univariate and multiple regression analyses were conducted.Results: The analysis included 107 drugs in Germany and 70 in France. In Germany, univariate analysis showed significance for benefit magnitude, orphan status, number of comparators, target population, and approval year. In France, orphan status, number of comparators, target population, and approval year were significant. Regression models showed that log target population (p < 0.0001), approval year (p = 0.021), and major/considerable benefit (p < 0.0001) were significant in Germany; log target population (p = 0.001) and ASMR II/III (p = 0.017) were significant in France.Conclusions: Target population and benefit rating are drivers of cancer drug prices in Germany and France. The analysis provides quantitative evidence on the association between cancer rarity and price, which could inform policy.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0